This article is more than 5 years old. Information may no longer be current.

FDA approves NDA for Acticlate

Aqua Pharmaceuticals announced that the U.S. Food and Drug Administration has approved a New Drug Application for the company’s tetracycline-class antibacterial.

Acticlate (doxycycline hyclate USP) 150 mg and 75 mg tablets, is indicated for the treatment of a number of infections, including adjunctive therapy in acne. The 150 mg tablets feature two functional scores to provide additional dosing options, according to a press release. The 75 mg dosage is a film-coated, round tablet, whereas the 150 mg dosage is an oval-shaped, dual-scored tablet designed to be easy for patients to swallow.

The company plans to begin reaching out to physicians in the coming weeks regarding Acticlate’s uses, according to the release.